SGK
MRNA icon

Steigerwald Gordon & Koch’s Moderna MRNA Stock Holding History

Steigerwald Gordon & Koch’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.5K Hold
150
– – ﹤0.01% 532
2026
Q1 		$7.62K Hold
150
– – ﹤0.01% 563
2025
Q4 		$4.42K Hold
150
– – ﹤0.01% 703
2025
Q3 		$3.88K Buy
+150
New +$4.18K ﹤0.01% 665

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Steigerwald Gordon & Koch's MRNA Position: Q2 2026 in Review

Steigerwald Gordon & Koch held its Moderna (MRNA) position steady in Q2 2026 at 150 shares worth $10.5K. The position accounts for ﹤0.01% of the portfolio, ranked #532.

Steigerwald Gordon & Koch first reported a position in MRNA in Q3 2025 and has held it in 4 quarters since. 784 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Steigerwald Gordon & Koch held 150 shares of Moderna worth $10.5K as of Q2 2026.
  • Steigerwald Gordon & Koch left its Moderna share count unchanged in Q2 2026.
  • Moderna made up ﹤0.01% of Steigerwald Gordon & Koch's portfolio in Q2 2026, its #532 holding.
  • Steigerwald Gordon & Koch first reported a position in Moderna in Q3 2025 and has held it in 4 quarters since.
  • 784 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Steigerwald Gordon & Koch's 13F filing for Q2 2026, filed 23 Jul 2026.